Cargando…
Recommendations for Regulating the Environmental Risk of Shedding for Gene Therapy and Oncolytic Viruses in Canada
Canadian academic and industry stakeholders are concerned about the inclusion of “virus-like particles or sub-viral particles” in the definition of New Substances Notification Regulations for Organisms (NSNR(O)) which impacts clinical cell and gene therapy and commercialization. The requirement of a...
Autores principales: | Bubela, Tania, Boch, Ron, Viswanathan, Sowmya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6447701/ https://www.ncbi.nlm.nih.gov/pubmed/30984761 http://dx.doi.org/10.3389/fmed.2019.00058 |
Ejemplares similares
-
Conditional Drug Approval as a Path to Market for Oncology Drugs in Canada: Challenges and Recommendations for Assessing Eligibility and Regulatory Responsiveness
por: McPhail, Melanie, et al.
Publicado: (2022) -
Canada's Assisted Human Reproduction Act: Pragmatic Reforms in Support of Research
por: Bubela, Tania, et al.
Publicado: (2019) -
Should Canada adopt managed access agreements in Canada for expensive drugs?
por: McPhail, Melanie, et al.
Publicado: (2023) -
Oncolytic Viruses: An Inventory of Shedding Data from Clinical Trials and Elements for the Environmental Risk Assessment
por: Onnockx, Sheela, et al.
Publicado: (2023) -
A clinical trial investigating biodistribution and shedding of an oncolytic virus
por: Reale, Alberto, et al.
Publicado: (2019)